Chase Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Chase Therapeutics General Information
Description
Operator of a pharmaceutical company intended to develop drugs for the treatment of brain disease. The company's novel compounds employ approaches to both symptomatic relief and disease modification, enabling doctors to treat those affected by central nervous system disorders and improve their quality of life.
Contact Information
Website
www.chasetherapeutics.comCorporate Office
- 1825 K Street Northwest
- Suite 510
- Washington, DC 20006
- United States
Corporate Office
- 1825 K Street Northwest
- Suite 510
- Washington, DC 20006
- United States
Chase Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 4. Early Stage VC (Series B) | 16-Dec-2021 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series A3) | 29-Oct-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A2) | 28-Aug-2018 | $4M | $5.3M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A1) | 21-Nov-2017 | $1.3M | $1.3M | Completed | Clinical Trials - Phase 1 |
Chase Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 2,000,000 | $0.000100 | $0.1 | $2 | $2 | 1x | $2 | 11.12% |
| Series A1 | 1,300,000 | $0.000100 | $0.05 | $1 | $1 | 1x | $1 | 7.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Chase Therapeutics Patents
Chase Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025145022-A1 | Compositions and methods for treating anhedonia | Inactive | 28-Dec-2023 | ||
| AU-2022293855-A1 | Diagnostic indices for neurodegenerative conditions | Inactive | 15-Jun-2021 | ||
| CA-3222315-A1 | Diagnostic indices for neurodegenerative conditions | Pending | 15-Jun-2021 | ||
| EP-4356143-A1 | Diagnostic indices for neurodegenerative conditions | Inactive | 15-Jun-2021 | ||
| EP-4356143-A4 | Diagnostic indices for neurodegenerative conditions | Inactive | 15-Jun-2021 | G16H50/20 |
Chase Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ChinaLink Capital | PE/Buyout | Minority | ||
| ChinaLink ESG T | Corporate Venture Capital | Minority |
Chase Therapeutics FAQs
-
When was Chase Therapeutics founded?
Chase Therapeutics was founded in 2017.
-
Where is Chase Therapeutics headquartered?
Chase Therapeutics is headquartered in Washington, DC.
-
What industry is Chase Therapeutics in?
Chase Therapeutics’s primary industry is Drug Discovery.
-
Is Chase Therapeutics a private or public company?
Chase Therapeutics is a Private company.
-
What is Chase Therapeutics’s current revenue?
The current revenue for Chase Therapeutics is .
-
How much funding has Chase Therapeutics raised over time?
Chase Therapeutics has raised $45.3M.
-
Who are Chase Therapeutics’s investors?
ChinaLink Capital and ChinaLink ESG T have invested in Chase Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process